VivoSeq
Other

First in Man Study

0

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

First in Man Study is an early-stage landscape with 0 programs across 3 companies. The most active players are Ablynx, a Sanofi company, Johnson & Johnson, Solvay Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

56/100

Attrition Rate

40/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Ablynx, a Sanofi company

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalS

Solvay Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed5 · 50%
Terminated4 · 40%
Unknown status1 · 10%

Clinical Trials

Trial Activity

10 trials

First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
Completed·IIndivior Inc.·Phase 1·NCT02765555·12 enrolled
A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours
Completed·RRoyal Marsden NHS Foundation Trust·Phase 1·NCT02437227·31 enrolled
ABX464 First in Man Study
Completed·—·Phase 1·NCT02792686·24 enrolled
99mTc-rhAnnexin V-128: a First In Man Study in Healthy Volunteers
Completed·—·Phase 1·NCT02182609·14 enrolled
A First in Man Study of MABp1 in Patients With Advanced Cancers
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT01021072·52 enrolled
First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10
Terminated·CCentre Leon Berard·Phase 1·NCT01469975·20 enrolled
First in Man Study With SLV342
Terminated·—·Phase 1·NCT00985478·48 enrolled
First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4
Terminated·AAblynx, a Sanofi company·Phase 1·NCT01374503·52 enrolled
First in Man Study With SLV341
Terminated·SSolvay Pharmaceuticals·Phase 1·NCT00887445·87 enrolled
68Ga-NOTA-PEG2-RM26 PET/CT, First in Man Study
Unknown status·KKarolinska University Hospital·Phase 1·NCT06147362·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)